

Pharmaceutical Actives and PFOS/PFOA - What Treatment Technologies are Working

Joseph G. Cleary, P.E., BCEE
AAEES Workshop at NJWEA Annual Meeting | May 6, 2019

Geosyntec 
consultants





Presentation Outline

- I. Introduction
- II. Active Pharmaceutical Ingredients (APIs)
- III. API Treatment Technologies and Case Studies
- IV. PFOS/PFOAs
- V. Technologies and Case Studies
- VI. Summary





What is an API?

- Active pharmaceutical Ingredients (API) are the bioactive chemical agents in our medicines
 - Drug products include pills, tablets, capsules, gels, ointments, oral suspensions & injectable solutions
- Anti-infectives and hormones are the most consequential for the environment
- Modern medicines are built on high potency API
 - Increasingly are high MW biological products
 - Used to be primarily “small molecules” from multi-step chemical synthesis



- APIs can be classified into three potentially harmful categories:
 - Toxic Compounds
 - Endocrine Disrupting Compounds (EDCs)
 - Anti-Infectives: Antibiotic & Antimicrobial Agents





The first clue that your new chemical might be an endocrine disruptor.

- Feminization of male fish (e.g. testis-ova induction)
- Modulation of endogenous hormones, receptors, and proteins
- Potential impacts on both human and environmental health

- AMR is the resistance of a microorganism to an AI which was originally effective for treatment
- 3 major causes:
 - Over-prescription in humans, inappropriate use (e.g. non-bacterial infections), & failure to complete treatment courses
 - Routine, non-therapeutic use in livestock
 - Releases of AI into wastewater from human/animal metabolism, pharma production discharges, improper disposal

United States population 300m

>23,000 deaths


>2.0m illnesses

Overall societal costs
Up to \$20 billion direct
Up to \$35 billion indirect




Source: US CDC 2013



Over the last 30 years, no major new types of antibiotics have been developed



Urban Water Cycle





- WWTPs designed to reduce loads of C, N, and P in the influent at concentrations of mg/L
 - API typically are present at concentrations in the ng/L to $\mu\text{g/L}$
 - Dilution is a factor in influencing degree of treatment
- Some API can be degraded >90% by activated sludge but many are only partially treated
- Physicochemical properties strongly influence both environmental fate and treatment technology selection
 - Polar groups (e.g. $-\text{OH}$, $-\text{COOH}$, $-\text{NH}_2$ etc.) enhance solubility, lessen sorption potential, impart reactivity (acid-base)
 - Degree of saturation of carbon framework
 - Presence of zwitterionic (both “+” and “-”) groups



- Significant solubility in water
- Progressively more hydrophilicity as pH increases
- No significant acid-base behavior
- Moderate sorption potential
- C:H ratio suggests a highly unsaturated C framework, multiple aromatic and olefinic C=C bonds
- Reasonably well biodegraded by AS
- Frequently found in WWTP effluent and in sludges (~1,000 µg/kg)
- Amine functions, multiple C=C bonds make ozone an excellent treatment option

- Aq. Sol. = 630 mg/L @ T=25°C
- Log K_{ow} = -0.16 @ pH 5 to -1.65 @ pH 9
- K_{oc} soil = 42,246-237,225



- Aq. Sol. = 4,363 mg/L @ T=25°C
- Log K_{ow} = 0.25-0.40

- Substantial aqueous solubility
- Relatively low sorption potential
- C:H ratio suggests a relatively saturated C framework, 1 aromatic ring & 2 azole groups
- A Chinese study of azole antifungals indicated pass through at the WWTP with little biodegradation or sorption to sludge
- Aromatic ring and fluorines will promote sorption & deactivate reactivity of ring
- Aromatic C=C bonds and amino functionality of azoles are good targets for ozone

Processes

1. API* - Organic Synthesis
2. API - Fermentation
3. DP** - Oral Solid Dosage
4. DP - Liquid Formulation
5. Type of Equipment Cleaning



Clean in Place (CIP) System

* API synthesis – 50 to 100%

** Drug Product (DP) – 10-50% for solids, dry wiping/vacuum cleaning
closer to 100% for liquids, liquid cleaning

Collect Wastewater at Point of Generation (POG)

- Collect 1st & 2nd equipment cleaning rinses before CIP
- Treatment (e.g., alkaline treatment, advanced oxidation)
- Zero liquid discharge – Evaporation Technology
- Off-site disposal (e.g., incineration)



- Minimize the use of liquid equipment cleaning
- Maximize the use of dry cleaning/vacuuming




API and excipient powder everywhere!




Removing residual API from filling reservoir of tablet press


Process Wastewater




Membrane Bioreactor Process




	Plant 1	Plant 2
Influent API (ug/l)	32.6	13
Effluent API (ug/l)	11	0.1
Sludge API (ug/l)	2	0.8
% Effluent	34	< 1
% Adsorbed to Sludge	< 1	< 1
% Volatilized (assumption)	0	0
% Biodegraded	66	99
Sludge Age (days)	15	29
Aeration Basin Temperature (°C)	26	30




Diclofenac




Sulfamethoxazole



Carbamazepine



17 α-Ethinylestradiol




Roxithromycin


*Huber et al., 2003,
Env.Sci.Technol.*

Run Number	Treatment Process	Compound Reduction	Toxicity Reduction
1	UV, hydrogen peroxide	99.5%	58%
2	Catalyzed UV, hydrogen peroxide	99.8%	88.2%
3	UV, ozone	99.4%	99.1%
4	UV, ozone, hydrogen peroxide	99.5%	95%

- Hormone Replacement Therapy (HRT):
 - Medroxy Progesterone Acetate (MPA), Trimegestone, 17- α -estradiol, 17- β -estradiol, 17- α -dihydroequilin and Estrone
- Oral Contraceptives (OC):
 - 17- α -ethinyl estradiol, Norgestrel, Gestodene, Estriol, Medrogestone and Estradiol Valerate
- Tranquilizers:
 - Oxazepam, Lorazepam and Lormetazepam


Case Study: Process Flow Diagram






2 GE/Zenon Z-500 C cassettes (0.04/0.1 micron pore size) with filtration area of 2,241 m² per cassette and header for 1 additional cassette per tank. There are 88 modules per cassette. RAS is 6Q.

Case Study: Yeast Estrogen Screen (YES) Results






Electrochemical AOP







- Core technology is based on electrochemical process
- Electricity is applied to advanced catalysts
- Catalysts generate oxidants to breakdown organics
- Organics oxidized to gases e.g. N₂, H₂, O₂, CO₂
- No other waste or by-products are generated
- Technology protected by an extensive patent portfolio

Introduction to the Nyex™ System



Case Study: Antibiotic Removal

Name	Removal (%)	Structure
Clarithromycin	96.3	 <p>The chemical structure of Clarithromycin is a complex macrolide antibiotic. It features a 14-membered macrolide ring with two methyl groups on the nitrogen atom, a hydroxyl group, and a trimethylammonium group. It is also linked to a 13-membered bicyclic ring system with multiple hydroxyl and methyl groups.</p>
Sulfamethoxazole	99.0	 <p>The chemical structure of Sulfamethoxazole consists of a benzene ring with an amino group (-NH₂) at the para position and a methoxy group (-OCH₃) at the other para position. It is also attached to a pyrimidine ring system with a nitro group (-NO₂) and a methyl group.</p>
Lincomycin	Below limit of detection	 <p>The chemical structure of Lincomycin is a lincosamide antibiotic. It features a six-membered lactam ring with a propyl group and a methyl group on the nitrogen atom. It is also linked to a five-membered ring system with a methylsulfanyl group (-SCH₃) and several hydroxyl groups.</p>
Ciprofloxacin	78.0	 <p>The chemical structure of Ciprofloxacin is a fluoroquinolone antibiotic. It features a central quinolone ring system with a fluorine atom, a piperazine ring, a cyclopropyl group, and a carboxylic acid group.</p>


At Source Treatment Screening Table

Table 6-1 Comparison of Non-Cost Criteria – At Source Treatment


At-source treatment		Screening Criteria					Total	Alternatives Selected or Rejected (preliminary)	Comments
		Proven Technology	Ability to Achieve Low Effluent Limits	Safety	East of operation				
Alternative 1	Alkaline Chlorination	3	2	3	2	10	Retain	Most proven and has been used by Pfizer on anti-fungals in Europe	
Alternative 2	Ozone	3	3	2	2	10	Retain	Proven in Puerto Rico and China and is another very good option. One chemical versus two for alkaline chlorination	
Alternative 3	Carbon	1	1	3	3	8	Retain	Effective for some APIs, but transfers to carbon.	
Alternative 4	Biological	1	1	3	3	8	Reject	Not used at all for at source only for total wastewater	
Alternative 5	Physical Chemical	1	1	2	2	6	Reject	It not a destructive technology, transfers APIs to sludge	
Alternative 6	Fenton's Chemistry	2	1	2	2	7	Retain	Proven chemical oxidation technology that can be used to create hydroxyl radicals that destroy APIs	
Alternative 7	UV Peroxide	2	2	2	2	8	Reject	Has been used instead of ozone but is not as commonly selected. Requires cleaning and maintenance of UV lamps	
Alternative 8	UV Ozone	3	3	2	2	10	Reject	More complicated than ozone by itself	
Alternative 9	Electrochemical AOP	1	1	1	1	4	Reject	No testing done on pharmaceutical wastewater	

Types of PFAS: Where do PFOA & PFOS fit?

Carboxylic Acids




Sulfonic Acids



And many more

- **PFAS have unique properties**
 - Hydrophobic and oleophobic
 - Persistent, bioaccumulative and toxic
 - Moderate solubility – can be transported long distances
- **Chemically and biologically stable**
 - Resistant to typical environmental degradation processes
 - C-F bond is shortest and strongest in nature
- **Treatment approaches challenging and costly**





Granular Activated Carbon

- Named Best Available Technology by EPA for organic contaminant removal
- Removes other organic contaminants
- Reactivation removes liability
- Minimal maintenance

Effective Products:

AquaCarb[®] CX Carbon

UltraCarb[®] 1240AW Carbon

UltraCarb[®] 1240LD Carbon




Single Pass Ion Exchange

- Lower EBCT / Higher flowrate
- Small footprint
- No chemicals or liquid waste
- Spent resin can be incinerated, destroying the contaminants (PFAS)
- Minimal maintenance

Effective Products:

PSR2 Plus

APR-2




Membranes

- Highly effective
- Removes dissolved solids

Effective Products:

Vantage[®] Product Line

PFC4 Resin vs GAC: Capacity (PFOA + PFOS)



INTERNATIONAL WATER CONFERENCE 2017

Resin Capacity is > 12 times that for CS-GAC

Boodoo, Francis & Kennedy, Sean & Campos, Jonathan. (2017). REMOVAL OF PFOA, PFOS AND OTHER PFAS SUBSTANCES USING ION EXCHANGE.



- Biological Treatment & Advanced Oxidation Process (AOP) are proven technologies for APIs
- At-Source Treatment is the best
- Estrogenicity & API removal of greater than 99.9% have been achieved in full scale treatment
- Carbon and Ion Exchange are best for PFOS/PFOA
- Treatability studies & process modeling tools are very helpful to develop design criteria & fate assessments

Thank You!

Jcleary@Geosyntec.com

